Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old
Robert W. Frenck(Naval Medical Research Command), William C. Gruber(Pfizer (United States)), Nicholas Kitchin(Johns Hopkins University), Kenneth Koury(Johns Hopkins University), Xia Xu(Pfizer (United States)), Kena A. Swanson(Pfizer (United States)), John L. Perez(AstraZeneca (France)), Shelly Senders(SUNY Upstate Medical University), Nicola P. Klein, Timothy A. Jennings(Clinical Research Associates), Stephen Lockhart(Johns Hopkins University), Kathrin U. Jansen(Pfizer (United States)), Philip R. Dormitzer(Boston Children's Hospital), Dina B Tresnan(Johns Hopkins University), Stephen J. Thomas(Global Viral), Susan Mather(Johns Hopkins University), Alejandra Gurtman(Johns Hopkins University), Warren V. Kalina(Pfizer (United States)), Donald M. Brandon(SUNY Upstate Medical University), Uğur Şahin(Johannes Gutenberg University Mainz), Judith Absalon(GlaxoSmithKline (United States)), Hua Ma(Pfizer (United States)), David Cooper(Johns Hopkins University), Özlem Türeci(Johannes Gutenberg University Mainz), Ruth Bailey(Johns Hopkins University), Emmanuel B. Walter(Duke University)
Cited by 3
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k